Polyethyleneimine-functionalized boron nitride nanospheres as efficient carriers for enhancing the immunostimulatory effect of CpG oligodeoxynucleotides

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 5343-5353

  Zhang, Huijie ^a   Feng, Shini ^a   Yan, Ting ^a   Zhi, Chunyi ^b   Gao, Xiao Dong ^a   Hanagata, Nobutaka ^c  

^a JIANGNAN UNIVERSITY   (China)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

Author keywords

Boron nitride nanosphere; CpG oligodeoxynucleotide; Cytokine; Immunostimulatory effect; Polyethyleneimine

Indexed keywords

ALPHA INTERFERON; BORON; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; INTERLEUKIN 6; NANOSPHERE; POLYETHYLENEIMINE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; BORON DERIVATIVE; BORON NITRIDE; CPG-OLIGONUCLEOTIDE; DRUG CARRIER; IL6 PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; IMMUNOSTIMULATION; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; STATIC ELECTRICITY; ZETA POTENTIAL; CHEMISTRY; DRUG EFFECTS; HUMAN; IMMUNE SYSTEM; INFRARED SPECTROSCOPY; METABOLISM; MONONUCLEAR CELL;

ADJUVANTS, IMMUNOLOGIC; BORON COMPOUNDS; DRUG CARRIERS; HUMANS; IMMUNE SYSTEM; INTERFERON-ALPHA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; NANOSPHERES; OLIGODEOXYRIBONUCLEOTIDES; POLYETHYLENEIMINE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940052795     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S88774     Document Type: Article

References (47)

1. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374(6522):546-549.
2. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4(4):248-257.
3. Hemmi H, Takeuchi O, Kawai T, et al. A toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740-745.
4. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999;73:329-368.
5. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675-680.
6. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996;93(7):2879-2883.
7. Bauer S, Kirschning CJ, Häcker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98(16):9237-9242.
8. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol. 1996;157(5):2116-2122.
9. Sun SQ, Zhang XH, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CgG DNA. J Exp Med. 1998;188(12):2335-2342.
10. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-760.
11. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev. 2009;61(3):256-262.
12. Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev. 2009;61(3):248-255.
13. Krieg AM. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5(6):471-484.
14. Murad YM, Clay TM. CpG oligodeoxynucleotides as TLR9 agonists therapeutic applications in cancer. Bio Drugs. 2009;23(6):361-375.
15. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynu-cleotides as immune adjuvants. Immunol Rev. 2004;199(1):201-216.
16. Mutwiri G, Littel-van Den Hurk SV, Babiuk LA. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv Drug Deliv Rev. 2009;61(3):226-232.
17. Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release. 2004;97(1):1-17.
18. Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine. 2012;7:2181-2195.
19. Sheehan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood. 1998;92(5):1617-1625.
20. Henry SP, Beattie G, Yeh G, et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol. 2002;2(12): 1657-1666.
21. Chopra NG, Luyken RJ, Cherrey K, et al. Boron-nitride nanotubes. Science. 1995;269(5226):966-967.
22. Golberg D, Bando Y, Tang CC, Zhi CY. Boron nitride nanotubes. Adv Mater. 2007;19(18):2413-2432.
23. Chen X, Wu P, Rousseas M, et al. Boron nitride nanotubes are noncytotoxic and can be functionalized for interaction with proteins and cells. J Am Chem Soc. 2009;131(3):890-891.
24. Jonsson E, Simonsen L, Karlsson M, Larsson R. The hollow fiber model: a new method for in vivo-evaluation of antitumor effect, toxicity and pharmacokinetics of new anticancer drugs. Ann Oncol. 1998;9: 44-44.
25. Gao ZH, Zhi CY, Bando Y, Golberg D, Serizawa T. Isolation of individual boron nitride nanotubes via peptide wrapping. J Am Chem Soc. 2010; 132(14):4976-4977.
26. Ciofani G, Raffa V, Menciassi A, Cuschieri A. Boron nitride nanotubes: an innovative tool for nanomedicine. Nano Today. 2009;4(1):8-10.
27. Ciofani G, Danti S, Nitti S, Mazzolai B, Mattoli V, Giorgi M. Biocompatibility of boron nitride nanotubes: an up-date of in vivo toxicological investigation. Int J Pharm. 2013;444(1-2):85-88.
28. Ciofani G, Danti S, Genchi GG, et al. Pilot in vivo toxicological investigation of boron nitride nanotubes. Int J Nanomedicine. 2012;7: 19-24.
29. Zhi CY, Meng WJ, Yamazaki T, et al. BN nanospheres as CpG ODN carriers for activation of toll-like receptor 9. J Mater Chem. 2011;21(14): 5219-5222.
30. Kerkmann M, Costa LT, Richter C, et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-α induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem. 2005; 280(9):8086-8093.
31. Putnam D, Gentry CA, Pack DW, Langer R. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci U S A. 2001;98(3):1200-1205.
32. Zhu J, Tang A, Law LP, et al. Amphiphilic core-shell nanoparticles with poly(ethylenimine) shells as potential gene delivery carriers. Bioconjug Chem. 2005;16(1):139-146.
33. Manoharan Y, Ji Q, Yamazaki T, et al. Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-alpha. Int J Nanomedicine. 2012;7:3625-3635.
34. Meng WJ, Yamazaki T, Nishida Y, Hanagata N. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human toll-like receptor 9 agonists. BMC Biotechnol. 2011;11:88.
35. Tang CC, Bando Y, Huang Y, Zhi CY, Golberg D. Synthetic routes and formation mechanisms of spherical boron nitride nanoparticles. Adv Funct Mater. 2008;18(22):3653-3661.
36. Zhu YF, Ikoma T, Hanagata N, Kaskel S. Rattle-type Fe(3)O(4)@ SiO(2) hollow mesoporous spheres as carriers for drug delivery. Small. 2010;6(3):471-478.
37. Brunot C, Ponsonnet L, Lagneau C, Farge P, Picart C, Grosgogeat B. Cytotoxicity of polyethyleneimine (PEI), precursor base layer of polyelectrolyte multilayer films. Biomaterials. 2007;28(4):632-640.
38. Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5(2): 190-198.
39. Zhang H, Chen S, Zhi C, Yamazaki T, Hanagata N. Chitosan-coated boron nitride nanospheres enhance delivery of CpG oligodeoxy-nucleotides and induction of cytokines. Int J Nanomedicine. 2013;8: 1783-1793.
40. Zhang H, Yamazaki T, Zhi C, Hanagata N. Identification of a boron nitride nanosphere-binding peptide for the intracellular delivery of CpG oligodeoxynucleotides. Nanoscale. 2012;4(20):6343-6350.
41. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001;31(10):3026-3037.
42. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164(3):1617-1624.
43. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA moth in human primary B cells. J Immunol. 2000;164(2): 944-952.
44. Guiducci C, Ott G, Chan JH, et al. Properties regulating the nature of the plasmacytoid dendritic cell response to toll-like receptor 9 activation. J Exp Med. 2006;203(8):1999-2008.
45. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005;434(7034): 772-777.
46. Klein DCG, Latz E, Espevik T, Stokke BT. Higher order structure of short immunostimulatory oligonucleotides studied by atomic force microscopy. Ultramicroscopy. 2010;110(6):689-693.
47. Chinnathambi S, Chen S, Ganesan S, Hanagata N. Binding mode of CpG oligodeoxynucleotides to nanoparticles regulates bifurcated cytokine induction via toll-like receptor 9. Sci Rep. 2012;2:534.